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Background: Hyperthermia (HT) causes a direct damage to cancerous cells and/or sensitize
them to radiotherapy with usually minimal injury to normal tissues. Adjuvant HT is prob-
ably one of the most effective radiation sensitizers known and works best when delivered
simultaneously with radiation. In breast conserving therapy, irradiation has to minimize
the risk of local relapse within the treated breast, especially in an area of a tumor bed.
Brachytherapy boost reduces 5-year local recurrence rate to mean 5,5%, so there still some
place for further improvement. The investigated therapeutic option is an adjuvant single
session of local HT (thermal boost) preceding standard CT-based multicatheter interstitial
HDR brachytherapy boost in order to increase the probability of local cure.
Aim: To report the short-term results in regard to early toxicity of high-dose-rate (HDR)
brachytherapy (BT) boost with or without interstitial microwave hyperthermia (MV HT) for
early breast cancer patients treated with breast conserving therapy (BCT).
Materials and methods: Between February 2006 and December 2007, 57 stage IA–IIIA breast
cancer patients received a 10Gy HDR BT boost after conservative surgery and 42.5–50Gy
whole breast irradiation (WBI)±adjuvant chemotherapy. 32 patients (56.1%) were treated
with additional pre-BT single session of interstitial MW HT to a tumor bed (multi-catheter
technique). Reference temperature was 43 ◦C and therapeutic time (TT) was 1h. Incidence,
severity and duration of radiodermatitis, skin oedema and skin erythema in groups with (I)
or without HT (II) were assessed, signiﬁcant p-value≤0.05.
Results: Median follow-up was 40 months. Local control was 100% and distant metastasis
free survival was 91.1%. HT sessions (median): reference temperature 42.2 ◦C, therapeutic
time (TT) 61.4min, total thermal dose 42min and a gap between HT and BT 30min. Radio-
dermatitis grades I and II occurred in 24 and 6 patients, respectively, differences between
groups I and II were not signiﬁcant. Skin oedema and erythema occurred in 48 (85.7%) and 36(64.3%) cases, respectively, and were equally distributed between the groups. The incidence
and duration of skin oedema differed between the subgroups treatedwith different fraction-
ation protocols of WBI, p=0.006. Skin oedema was present up to 12 months. No difference
in pattern of oedema regression between groups I and II was observed, p=0.933.
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Conclusion: Additional thermal boost preceding standard HDR BT boost has a potential of
further improvement in breast cancer local control in BCT. Pre-BT hyperthermia did not
increase early toxicity in patients treated with BCT and was well tolerated. All side effects
of combined treatment were transient and were present for up to 12 months. The increase
in incidence of skin oedema was related to hypofractionated protocols of WBI. The study
has to be randomized and continued on a larger group of breast cancer patients to verify
the potential of local control improvement and to assess the proﬁle of late toxicity.
© 2011 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.
z.o.o. All rights reserved.1. Background
Hyperthermia (HT) is one of the cancer therapies and, clin-
ically, is considered to be an artiﬁcial way of increasing the
temperature of a particular tumorous region over the physio-
logical temperature of the body.1–3 It is achieved by delivering
heat obtained from external sources, e.g. microwaves (MW).
HT is mostly understood as a range of temperatures from 40
to 48 ◦C maintained in a treated site for a period of about an
hour.4–8
Many studies have already shown that high temperature6
cause a direct damage to cancerous cells and/or sensitize
them to other treatmentmodalities (radiotherapy, chemother-
apy, gene therapy and immunotherapy) usually with minimal
or no injury to normal tissues.4,7–12 Thus, HT is extensively
used as an adjuvant therapy.2,5,9 HT has a potential of killing
cells itself, induces reoxygenation, increases radiosensitiv-
ity and augments immune reactions against the tumor.13–15
In fact, hyperthermia is probably one of the most effective
radiation sensitizers known, a fact supported with extensive
preclinical data and a number of large randomized clinical
trials.16,17 The most probable mechanism by which HT sen-
sitizes cells to radiation is by interfering with the cells’ ability
to repair radiation-induced damage of DNA structure,18 as
predominant target of HT is protein.8,9,19 Due to a temporary
effect of heat-induced changes in protein structure, the best
approach is to deliver hyperthermia and radiation simultane-
ously, which is difﬁcult in common practice.
Breast conserving therapy (BCT), consisting of conservative
surgery, radiotherapy±brachytherapy and optional adjuvant
chemotherapy, is a standard radical treatment for a vast
majority of breast cancer patients. BCT is a good alternative to
mastectomy in treatment of early invasive breast cancer.20–22
The goal of irradiation is to minimize the risk of local relapse
within the treated breast, especially in an area of a tumor bed
which is a target volume for brachytherapy. There are many
methods of increasing the dose to the tumor bed (boost).23 The
best approach is chosen depending on clinical and morpho-
logical criteria, patient’s will and institutional resources and
protocols,. Modern interstitialmulti-catheter HDR brachyther-
apy offers conformal and accurate irradiation of the target
volume, provided there are surgical clips left in the operated
breast and treatment planning system is CT-based. Patient age
of <50years; close, microscopically positive or unknown sur-
gical margins; and the presence of an extensive intraductal
component are accepted indications for boost irradiation.24–26Randomized “boost vs. no boost” trials revealed, that there
is an evident beneﬁt from administering additional dose to
the tumor bed. The boost reduces 5-year local recurrence rate
from7.3–13.3% to 3.6–6.3% (p 0.04–0.0001).27–29 Polgár et al. also
summarized the results of many different HDR brachytherapy
series worldwide, in which in total 1776 patients, 5-year local
recurrence rate was achieved in 0–9% (mean 5.5%).26 There is
still some room for improvement in common management of
early stage breast cancer in order to decrease the recurrence
rate to a minimum level. This goal can be achieved by eradi-
cating the gross tumor and all cancer cells in its surrounding
(margins of healthy tissue). One of the investigated therapeu-
tic options is additional local hyperthermia which has already
proved its potential of improving the outcome of standard
therapy. The main objective of such research is to ﬁnd an opti-
mal treatment which would enable achieving of up to 100%
local control.
Sophisticated CT-based interstitial brachytherapy of breast
cancer is based on multi-catheter implants piercing the tumor
bed. The same set of elastic tubes can be successfully used
for hyperthermia treatment. In this approach, tiny microwave
antennas are inserted into the treated volume via brachyther-
apy applicators. The antennas always have to be used along
with thermometers inserted for temperature measurement
and adjustments. A set of CT scans used for treatment
planning delivers strict geometrical information about 3D ori-
entation of applicators within the tumor bed and enables the
physician to plan the best pattern of antennas and thermome-
ters to safely heat the target volume before irradiation. It was
decided to add a single hyperthermia session (thermal boost)
preceding standard brachytherapy boost in order to increase
the probability of local cure.
2. Aim
To report the short-term results in regard to early toxicity of
high-dose-rate (HDR) brachytherapy (BT) boost with or with-
out interstitial microwave hyperthermia (HT) for early-stage
breast cancer patients treated with breast conserving therapy
(BCT).
3. Materials and methodsBetween February 2006 and December 2007, 57 early-stage
breast cancer patients were treated with HDR BT boost after
BCT, followed by external beam radiotherapy (EBRT) to the
reports of practical oncology and rad
Table 1 – Patient and tumor characteristics.
n=57 (100%)
Age, median (range) 53 (32–71) years
≤40 5 (8.8%)
41–50 13 (22.8%)
51–60 21 (36.8%)
≥61 18 (31.6%)
T stage
T1a 2 (3.5%)
T1b 11 (19.3%)
T1c 33 (57.9%)
T2 8 (14%)
Tx 3 (5.3%)
N stage
N0 37 (64.9%)
N1 17 (29.8%)
N2 3 (5.3%)
Clinical stage
IA 27 (47.4%)
IB 1 (1.7%)
IIA 21 (36.8%)
IIB 2 (3.5%)
IIIA 3 (5.3%)
ns 3 (5.3%)
Tumor histology
Invasive ductal carcinoma 47 (82.5%)
Invasive lobular carcinoma 2 (3.5%)
Tubular carcinoma 4 (7%)
Other 4 (7%)
Tumor grade
G1 20 (35.1%)
G2 24 (42.1%)
G3 10 (17.5%)
Gx 3 (5.3%)
Receptor status
ER pos/neg/ns 39 (68.4%)/15 (26.3%)/3 (5.3%)
PgR pos/neg/ns 36 (63.1%)/18 (21.6%)/3 (5.3%)
HER2 1+/2++/3+++ 18 (31.6%)/10 (17.5%)/1 (1.7%)
neg/ns 13 (22.8%)/15 (26.4%)
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aAbbreviation: ns – not speciﬁed, ER – estrogen receptor, PgR – pro-
gesterone receptor, neg – negative, pos – positive.
hole breast (WBI) and in 34 cases (59.6%) by chemotherapy,
f indicated. All patients underwent conservative surgery with
xillary lymph nodes dissection in vast majority of them. In 5
atients (8.8%) sentinel node biopsies (SNB) were performed.
etailed clinical and pathological data are listed in Table 1.
ll except 3 patients were treated with hypofractionated reg-
mens of EBRT. Equivalent total doses normalized to 2Gy per
aily fraction were similar, ranging from 46 to 50Gy (Table 2).
atients were irradiated according to a 3D conformal tech-
ique conventionally delivered in opposed tangential ﬁelds
ith photon energy of 6MV.
All 57 patients were administered 10Gy single frac-
ion boost with radioactive source of 191Ir (remote after-
oader microSelectron HDR, Nucletron BV, Veenendaal, the
etherlands). The method of implantation (multi-catheter
echnique) and treatment planning are described in details
lsewhere.24 32 patients (56.1%) were selected for interstitial
W hyperthermia preceding brachytherapy boost. Selection
as not randomized and based on clinical performance of
he patients and their informed consent. Final decisions to
dd hyperthermia had been made after implantation of elas-iotherapy 1 6 ( 2 0 1 1 ) 87–94 89
tic tubes into the breast gland. Patients with sufﬁciently large
breasts, in which minimal skin-to-skin interstitial applicator
distances were found to be at least 6–7 cm. It was done in
order to avoid unintended heating of the skin (risk of blisters)
as active length of interstitial MW antennas is about 4.5 cm.
Such approach leads to skin sparing and eliminates pain
complaints during a HT session. Details concerning treated
locations (quadrants) are listed in Table 2.
Each HT session was planned to last about 90min, includ-
ing preparation and insertion of antennas and thermometers
into the tubes. Proper catheters were selected to be implanted
with active MW antennas or thermometers after the assess-
ment of post-implant CT scans to appropriately cover tumor
bed with intended pattern of isotherms. Hypothetical ideal
temperature distribution within heated volume is presented
in Fig. 1. Prescribed reference temperature was 43 ◦C. Intended
therapeutic time (TT, the time with temperature maintained
above 40 ◦C) was 1h and the time interval between the termi-
nation of heating and the start of HDR irradiation was as short
as reasonably possible.
Themedian follow-up for all patientswas 40months (range
1–49 months). Patients were investigated (clinical examina-
tion, blood samples, photo documentation) every 3 months
in the ﬁrst 2 years after the treatment and every 6 months
in the following years. First mammography (for monitoring
of local relapse, necrosis and/or ﬁbrosis) was scheduled 6–12
months after the completion of treatment and then annually.
Special attention of the study was paid to early toxicity of
the treatment. Incidence of late toxicity and cosmetic results
are to be reported in the future after substantially longer
follow-up. Presence, severity and duration of radiodermati-
tis, skin oedema and erythema after completed treatment
were assessed (individual impact of surgery on the presence
and severity of oedema was not speciﬁcally analyzed). The
key point of the paper is to assess the difference between
the incidence of symptoms listed above in the group of
patients treated with a standard BT boost and that in the
group with additional thermal boost. Mann–Whitney U-test
was used to evaluate the differences between the groups. The
Kaplan–Meiermethodwasused to calculate the actuarial rates
and patterns of healing in symptomatic patients with breast
oedema. A p-value of ≤0.05 was considered statistically signif-
icant.
4. Results
56 patients were included in the calculations as one patient
was observed in other institution: 24 patients treated with a
standardHDRBTboost (group I) and 32with additionalHTpre-
ceding BT (group II). During a median follow-up of 40 months,
none of the patients developed local recurrence. 5 patients
(8.9%) developed distant metastases: 2 and 3 in groups I and
II, respectively (Table 3). All patients were alive at the time of
analysis.
The most frequent location of thermal boost was upper lat-
eral quadrant. HT was prescribed only once in case of a tumor
bed located in the lower medial quadrant (Table 2). There was
a noticeable trend in the difference between groups I and II in
respect to treated quadrants (p=0.064, Fisher’s exact test).
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Table 2 – Treatment protocols and treated sites.
BT-HDR boost 10 Gy All 57 patients (100%)
HT Tref 43 ◦C/60 min 32 (56.1%)
EBRT
50Gy/#2Gy [EQD2 50.0Gy] 3 (5.3%)
45Gy/#2.25Gy [EQD2 46.9Gy] 19 (33.3%)
42,5Gy/#2.5Gy [EQD2 46.0Gy] 35 (61.4%)
Chemotherapy
Yes 34 (59.6%)
No 23 (40.4%)
All BT-HDR+HT BT-HDR alone
Tumor location (breast)
Right 27 (47.4%) 12 (21.1%) 15 (26.3%)
Left 30 (52.6%) 20 (35.1%) 10 (17.5%)
Tumor location (quadrant)
ULQ 29 (50.9%) 18 (31.6%) 11 (19.3%)
UMQ 6 (10.5%) 5 (8.8%) 1 (1.7%)
LLQ 9 (15.8%) 5 (8.8%) 4 (7%)
LMQ 8 (14%) 1 (1.7%) 7 (12.3%)
RA 5 (8.8%) 3 (5.3%) 2 (3.5%)
eral qTotal 57 (100%)
Abbreviation: Tref – reference temperature set at 43 ◦C, ULQ – upper lat
LMQ – lower medial quadrant, RA – retroareolar.
Median number of interstitial MW antennas used for HT
sessions was 3 and median number of thermometers was 3,
as well. Median reference temperature reached 42.2 ◦C and
median therapeutic time (TT)was 61.4min, which enabled the
treated volume to be delivered with median 42min of total
thermal dose. Median gap between HT and BT was 30min
(Table 4).
Fig. 1 – Temperature distribution within the tumor bed. Left 1–4:
within the tumor bed during single hyperthermia session. Uppe
thermometers inserted into interstitial ﬂexible applicators. Lowe
antenna (BSD-500, MW hyperthermia system operating on 915M32 (56.1%) 25 (43.9%)
uadrant, UMQ – upper medial quadrant, LLQ – lower lateral quadrant,
Radiodermatitis occurred in 30 patients, grades I and II in
24 and 6 patients, respectively. Distribution of radiodermatitis
amongst groups slightly differed, but the differences were not
signiﬁcant. The incidence and duration of skin oedema was
similar in both groups. Similar results were found for the inci-
dence and duration of skin erythema (for details see Table 3).
One signiﬁcant difference in incidence and duration of skin
hypothetical “ideal” increase in temperature distribution
r right: a set of microwave (MW) antennas and
r right: a schematic distribution of isotherms around the
Hz, BSD Medical).
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Table 3 – Observation results, n=56.a
BT alone group I BT+HT group II [p]
Radiodermatitis
Grade 0 13 (54.2%) 13 (40.6%) 0.432 (ns)
Grade I 12 (37.5%) 19 (46.9%) 0.505 (ns)
Grade II 2 (8.3%) 4 (12.5%) 0.676 (ns)
Oedema, yes/no (%) 21/3 (87.5%) 27/5 (84.4%) 0.933 (ns)
Duration, median (range) 4 (1–11) months 4 (1–12) months 0.721 (ns)
Skin erythema yes/no (%) 16/36 (66.7%) 20/32 (62.5%) 0.811 (ns)
Duration, median (range) 1 (0–8) months 1 (0–10) months
Local control (all, n=56) 100% 100% ns
Local control (min. 1 year)b 100% 100% ns
Distant metastases 2/24 (8.3%) 3/32 (9.4%) ns
Follow-up, median (range) 40 (3–49) months
a One patient out of 57 was followed-up only once after one month and was excluded from analysis.
b Local control in patients with minimum 1 year long observation, n=49/56 (in ﬁrst year of follow-up metastases occurred in 3 patients, 4
patients were not observed after the oedema regressed).
Abbreviations: ns – not signiﬁcant.
Table 4 – Details of delivered hyperthermia sessions.
Treated patients 32/57 (56.1%)
MW antennas; median (range) 3 (0–6)a
Interstitial thermometers; median (range) 3 (1–6)a
Mean MW energy; median (range) 3,7 (1.4–5.7) Watt
Reference temperature; mean/median (range) 41,6/42,2 (39.2–42.8) ◦C
Therapeutic TT (≥40 ◦C); median (range) 61.4 (0–65.3) min
Total thermal dose; median (range) 42 (0–60)min
Gap between HT and BT; median (range) 30 (5–60)min
a In one patient superﬁcial MW applicator and interstitial thermometers were used.
Abbreviations: MW – microwaves, TT – treatment time, HT – hyperthermia, BT – brachytherapy.
Table 5 – Incidence of oedema due to total dose and fractionation of external beam radiotherapy (EBRT).
o
s
a
5
s
F
p
duration of skin oedema also differed between the subgroupsTotal/fraction dose 42.5/2.5Gy
Oedema, yes/no (%) 33/34 (97.1%)
HT, yes/no (%) 19/15 (55.9%)
edema was revealed for groups with or without concomitant
kin erythema. In 34 patients who developed both oedema
nd erythema, the former lasted signiﬁcantly longer (median:
months) in comparison with a group of 14 patients with
olitary oedema (2.5 months), p=0.044. The incidence and
ig. 2 – Duration of breast oedema in all symptomatic
atients, n=48 (both groups).45/2.25Gy 50/2Gy [p]
13/19 (68.4%) 2/3 (66.7%) 0.006
12/7 (63.2%) 0/3 (0.0%) nsof patients who had been treated with different fractionation
protocols of EBRT. The shorter was the course of radiother-
apy and the higher the fraction dose, the more severe and
Fig. 3 – Duration of oedema in symptomatic patients (n=48)
in groups treated with brachytherapy alone (BT) or with
combination with hyperthermia (BT+HT).
nd ra92 reports of practical oncology a
longer lasting was the breast oedema, without any inﬂuence
of additional HT, p=0.006 (Table 5).
Skin oedema itself occurred in 48 cases (85.7%) and per-
sistedup to 12months. It healedmost often (71.4%) during ﬁrst
6 months of observation (Fig. 2). There was no difference in
pattern of oedema regression between groups I and II, p=0.933
(Fig. 3).
5. Discussion
In 2007, Horsman and Overgaard16 presented a review of
pre-clinical rationale for combining HT with radiation and
summarized the clinical data showing its efﬁcacy. A meta-
analysis of 23 published trials, in which 1861 patients were
randomized to thermoradiation or radiation alone, showed
a highly signiﬁcant improvement in locoregional control
(p<0.0001). It is relevant for many anatomical sites like the
breast and chest wall, cervix, rectum, bladder, melanoma,
glioblastoma and head and neck. In case of head and neck and
pelvic tumors, 3 studies reported signiﬁcant improvement also
in overall survival.30–33
Amongst the above, Vernon et al.34 presented a large breast
study that reported results from ﬁve randomized trials which
failed to prove beneﬁt in overall survival, but showed a clear
improvement in local control when HT had been added to
radiation.
It is worth noticing that none of the studies found any sig-
niﬁcant increase in acute toxicity31–37 and only one reported
a slight increase in late reactions.32 HT delivered alone or in
combination with other cancer treatments is generally well
tolerated and, if the temperature does not exceed 44.0 ◦C,
rarely affects normal tissues. Only higher thermal depositions
can lead to blistering, burns, pain ornecrosis.8,12 Results of this
paper stand in agreement with the above with regard to early
toxicity.
As regards breast cancer radiosensitivity, Niedbala et al.38
presented interesting data concerning response to PDR and
LDR with and without mild HT (41 ◦C) using two human breast
carcinoma cell lines: MCF7 (parental wild type) and the vari-
ant C716 (more radioresistant over-expressing a DNA repair
enzyme polymerase ). The study showed that the PDR and
LDR treatment combined with mild HT caused signiﬁcant
radiosensitization when compared to PDR and LDR irradia-
tion alone in terms of the clonogenic and comet assays with
both cell lines. This supports the concept of the inhibition of
DNA damage repair mechanisms in cells exposed to elevated
temperature.
A vast majority of available data concerning HT in breast
cancer treatment is focused on unoperable, locally advanced
or recurrent malignancies. Hartmann et al.39 investigated
breast conservation rates after preoperative chemotherapy,
radiotherapy and hyperthermia in 158 patients with stage
IIA–IV breast cancers. Radiation treatment involved an inter-
stitial brachytherapy boost of 10Gy immediately preceded
with a local hyperthermia session (43.5–44.5 ◦C over 60min)
and a course of external beam radiotherapy of 50Gy (5×2Gy
weekly). 142/158 patients underwent salvage surgery. In 74
(52%) breast-conserving therapy was possible, in 53 (37%) ﬂap-
supported surgery was done. After a median follow-up of 20diotherapy 1 6 ( 2 0 1 1 ) 87–94
months one patient (0.6%) developed isolated local recurrence
and in 14 patients locoregional recurrences occurred in com-
bination with distant metastases.
Dooley et al.12 presented fresh data emerging from their
randomized study on externally applied focused microwave
thermotherapy (FMT) for preoperative treatment of early-
stage invasive breast cancer. Interim results of the study
(assessed 75 patients out of 222 planned) are suggestive of a
reduction in positive margins in the preoperative thermother-
apy plus BCT arm compared with surgery alone (0 vs. 9.8%,
p=0.13).
Jones et al.40 presented a novel therapeutic program for
locally advanced breast cancer. 18 patients were given concur-
rent chemotherapy, HT and radiation followed bymastectomy.
Radiation therapy consisted of 50Gy delivered from external
ﬁelds and a boost to 60–65Gy for those not undergoing surgery.
HT was administered twice a week and tumor oxygenation
was measured. 15/18 patients responded with complete (6)
and partial (9) response. 13/18 patients underwent mastec-
tomy with 3 pathological complete responses. As stated in
conclusion, HT may offer a strategy for improving tumor oxy-
genation with consequent treatment response, which may
depend on thermal dose. The latter was continued by Jones
et al.41 in a prospective randomized trial of superﬁcial tumors
(≤3 cm depth) comparing radiotherapy vs. HT combined with
radiotherapy, using the parameter describing the number
of cumulative equivalent minutes at 43 ◦C exceeded by 90%
of monitored points within the tumor (CEM 43 ◦C T90) as a
measure of thermal dose, as trials generally lack rigorous ther-
mal dose prescription and administration. 121 patients were
enrolled; 109 (89%) were deemed heatable and were randomly
assigned. The complete response rate was 66.1% in the HT
arm (microwave spiral strip applicators, 433MHz) and 42.3% in
the no-HT arm. Previously irradiated patients had the great-
est incremental gain in complete response: 23.5% no-HT arm
vs. 68.2% HT arm. No overall survival beneﬁt was seen. They
concluded that adjuvant hyperthermia with a thermal dose of
more than 10 CEM 43 ◦C T90 confers a signiﬁcant local control
beneﬁt in patients with superﬁcial tumors receiving radiation
therapy. CEM 43 ◦C T90 appears to be the most useful dosimet-
ric parameter in clinical research.1,42,43 RTOG guidelines being
in force precisely describe rules of thermometry necessary for
CEM calculations and assurance of hyperthermia quality.8,44
Ben-Yosef et al.45 reported a simple and convenient ther-
moradiation delivery system to treat locally recurrent breast
cancer. They treated 15 women with external beam radiother-
apy (electrons or photons, total dose 30–40Gy in previously
irradiated ﬁelds or 50–70Gy in non-irradiated ﬁelds) followed
by at least two hyperthermia sessions to each HT ﬁeld (45 ◦C
over 45min started within 10min after irradiation, no inva-
sive thermometry). As a result, 10/15 patients had complete
or partially-inﬁlled response. The only major side effect was
ulceration in 3 patients (one healed, one remained and one
developed recurrence).
Arunachalam et al.46 went a step further. Over the years,
they designed and improved a novel ThermoBrachyther-
apy Surface Applicator (TBSA) for combined simultaneous
thermobrachytherapy of diffuse chest wall recurrences. MW
hyperthermia delivered simultaneously with HDR brachyther-
apy enables the increase of the thermal enhancement ratio
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TER) of the latter from 1.5 to 2.5 or higher. The method of
elivering hyperthermia described in this paper has to be
equentional as the same applicators are used for insert-
ng heating antennas and a stepping source of iridium. This
equires the time between hyperthermia session and the start
f irradiation to be as short as possible. With proper work ﬂow
he time interval can be as short as 5min.
At this point in time, hyperthermia is being combined
ith radiation therapy, chemotherapy or radiochemotherapy
nd, most lately, with gene or immunotherapy.4,5,7,9–11 Still,
ll the regimens have a status of scientiﬁc research or clini-
al trials.8 Despite a strong rationale for combining HT with
adiation, HT is still an out-of-routine clinical practice. One
f the reasons for that may be the need to have a high qual-
ty equipment, which has to be operated by dedicated andwell
rained personnel,8,16 HT sessions are obviously time consum-
ng and rarely reimbursed.45 Some more clinical trials have to
e closed and summarized to ﬁrmly re-conﬁrm hyperthermia
s a standard cancer treatment.
. Conclusion
dditional thermal boost preceding standard high-dose-rate
rachytherapy boost has a potential of further improvement
n breast cancer local control in breast conserving therapy.
single session of interstitial hyperthermia before BT boost
id not increase early toxicity in patients treated with BCT.
uch treatmentwas feasible andwell tolerated. All side effects
f combined treatment were transient and healed sponta-
eously in up to 12 months. The increase in the incidence
f skin oedema was related to hypofractionated protocols of
xternal whole breast irradiation. To verify the potential of
ocal control improvement and to assess the proﬁle of late tox-
city, the study has to be randomized and continued on a larger
roup of breast cancer patients.
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